Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RPA1 | P27694 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345937 | 0.79 | NPC1 (0.39) | NOTUMCASP3NPC1RAB9ASENP8 | |
| SCHEMBL2207084 | 0.79 | NPC1 (0.42) | NOTUMCASP3NPC1RAB9ANR1H4 | |
| SCHEMBL1435754 | 0.79 | TSHR (0.33) | — | |
| SCHEMBL30206 | 0.78 | RAB9A (0.44) | NOTUMCASP3NPC1RAB9ANR1H4 | |
| SCHEMBL5551743 | 0.77 | IDO1 (0.45) | NOTUMNPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL5552048 | 0.75 | S1PR1 (0.45) | NOTUMCASP3SIRT2 | |
| SCHEMBL5548169 | 0.75 | NOTUM (0.41) | NOTUM | |
| SCHEMBL5901769 | 0.75 | NPC1 (0.46) | NOTUMNPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL1435608 | 0.69 | HPGDS (0.39) | NPC1RAB9A | |
| SCHEMBL3618137 | 0.69 | CYP2A6 (0.39) | CASP3SENP8SENP7SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247811-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-09-27 | — | — | EP | claimed |
| US-20230278997-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | claimed |
| CN-116406359-A | Bicyclo [1.1.1] pentanes for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2023-07-07 | — | — | CN | claimed |
| WO-2022106375-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-05-27 | — | — | WO | claimed |
| US-9949955-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-04-24 | — | — | US | claimed |
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2016-11-24 | — | — | US | claimed |
| US-9439890-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-09-13 | — | — | US | claimed |
| US-9399648-B2 | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-26 | — | — | US | claimed |
| EP-2187884-B1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2016-03-30 | — | — | EP | claimed |
| EP-2718284-B1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS SA (CH) | 2015-11-18 | — | — | EP | claimed |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-24 | — | — | US | claimed |
| US-20050101778-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2005-05-12 | — | — | US | claimed |
| WO-2004106337-A1 | XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | WO | claimed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | claimed |
| CN-1434813-A | Pyrrolidine derivatives cyclic AMP-specific phosphodiesterase inhibitors | ICOS CONP (US) | 2003-08-06 | — | — | CN | claimed |
| JP-2003519135-A | — | — | 2003-06-17 | — | — | JP | claimed |
| EP-1242400-A1 | PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001047905-A1 | PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2001-07-05 | — | — | WO | claimed |
| EP-0422843-B1 | 6-0 Methylerythromycin A oxime derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1995-02-15 | — | — | EP | claimed |
| EP-0422843-A2 | 6-0 Methylerythromycin A oxime derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1991-04-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | NOTUM 666/4885CASP3 4082/4885NPC1 1186/4885 |
| US-20050101778-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | NOTUM 4451/4885CASP3 3449/4885NPC1 2702/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | NOTUM 3850/4885CASP3 3988/4885NPC1 2057/4885 |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | NOTUM 3708/4885CASP3 4063/4885NPC1 2104/4885 |
| US-20230278997-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP1B1, CYP7A1 | NOTUM 1768/4885CASP3 530/4885NPC1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.